Abbott/FDA meeting
Executive Summary
On March 22, company execs met with Commissioner Young, CDER Director Carl Peck, MD, and CBER Director Paul Parkman, MD, to discuss Abbott's research with AIDS treatments and the approval process for drugs for life-threatening diseases. In its AIDS work, Abbott has reportedly been pursuing mapping projects similar to the Merck project publicized earlier this year. Discussion also included Abbott's research on AIDS diagnostics, including the review of the firm's HIV Antigen test, which was recommended for approval by FDA's Blood Products Advisory Committee on March 23 for diagnostic and prognostic use with AIDS patients.